Home Clinical Research Current Clinical Trails A Phase I/II, First-in-Human, Open-Label, Dose Escalation Study of ZL-1211 in Patients with Unresectable or Metastatic Solid Tumor

A Phase I/II, First-in-Human, Open-Label, Dose Escalation Study of ZL-1211 in Patients with Unresectable or Metastatic Solid Tumor

Condition: CLDN18.2 broadly expressed in various cancer types, GC, biliary duct, pancreatic, ovarian, and a subset of non-small cell lung cancers (NSCLC) | Last Updated: | Status:

View Full Study